These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1707 related items for PubMed ID: 32326806

  • 1. Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment.
    Ikonomidis I, Pavlidis G, Thymis J, Birba D, Kalogeris A, Kousathana F, Kountouri A, Balampanis K, Parissis J, Andreadou I, Katogiannis K, Dimitriadis G, Bamias A, Iliodromitis E, Lambadiari V.
    J Am Heart Assoc; 2020 May 05; 9(9):e015716. PubMed ID: 32326806
    [Abstract] [Full Text] [Related]

  • 2. Impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment.
    Hiramatsu T, Ito H, Okumura S, Asano Y, Iguchi D, Furuta S.
    Diab Vasc Dis Res; 2020 May 05; 17(6):1479164120971220. PubMed ID: 33371732
    [Abstract] [Full Text] [Related]

  • 3. Effects of Liraglutide, Empagliflozin and Their Combination on Left Atrial Strain and Arterial Function.
    Katogiannis K, Thymis J, Kousathana F, Pavlidis G, Korakas E, Kountouri A, Balampanis K, Prentza V, Kostelli G, Michalopoulou H, Tsilivarakis D, Lambadiari V, Ikonomidis I.
    Medicina (Kaunas); 2024 Feb 26; 60(3):. PubMed ID: 38541121
    [Abstract] [Full Text] [Related]

  • 4. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V, Elharram M, Moura CS, Abrahamowicz M, Bernatsky S, Behlouli H, Pilote L.
    J Am Heart Assoc; 2020 Jan 07; 9(1):e012940. PubMed ID: 31902326
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence.
    Natali A, Nesti L, Tricò D, Ferrannini E.
    Cardiovasc Diabetol; 2021 Sep 28; 20(1):196. PubMed ID: 34583699
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. GLP-1 receptor agonists-SGLT-2 inhibitors combination therapy and cardiovascular events after acute myocardial infarction: an observational study in patients with type 2 diabetes.
    Marfella R, Prattichizzo F, Sardu C, Rambaldi PF, Fumagalli C, Marfella LV, La Grotta R, Frigé C, Pellegrini V, D'Andrea D, Cesaro A, Calabrò P, Pizzi C, Antonicelli R, Ceriello A, Mauro C, Paolisso G.
    Cardiovasc Diabetol; 2024 Jan 06; 23(1):10. PubMed ID: 38184582
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
    Verma S, Mazer CD, Yan AT, Mason T, Garg V, Teoh H, Zuo F, Quan A, Farkouh ME, Fitchett DH, Goodman SG, Goldenberg RM, Al-Omran M, Gilbert RE, Bhatt DL, Leiter LA, Jüni P, Zinman B, Connelly KA.
    Circulation; 2019 Nov 19; 140(21):1693-1702. PubMed ID: 31434508
    [Abstract] [Full Text] [Related]

  • 15. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
    Li CX, Liang S, Gao L, Liu H.
    PLoS One; 2021 Nov 19; 16(2):e0244689. PubMed ID: 33606705
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effect of Hemoglobin A1c Reduction or Weight Reduction on Blood Pressure in Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Treatment in Type 2 Diabetes Mellitus: A Meta-Analysis.
    Hu M, Cai X, Yang W, Zhang S, Nie L, Ji L.
    J Am Heart Assoc; 2020 Apr 07; 9(7):e015323. PubMed ID: 32223390
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Sodium-glucose co-transporter-2 inhibitors and the risk of venous thromboembolism: A nationwide population-based study and meta-analysis.
    Tsai HR, Lin YJ, Yeh JI, Huang YC, Liu PP, Peng CC, Hsu JY, Lee YC, Loh CH, Lin SM, Huang HK.
    Diabetes Metab Res Rev; 2024 Feb 07; 40(2):e3739. PubMed ID: 37862117
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 86.